Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 10

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Diabetes. Oct 15, 2023; 14(10): 1573-1584
Published online Oct 15, 2023. doi: 10.4239/wjd.v14.i10.1573

Full Size Figure Download Figure

Figure 1 Flow chart of this indirect meta-analysis.

Citation: Lin C, Li ZL, Cai XL, Hu SY, Lv F, Yang WJ, Ji LN. Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis. World J Diabetes 2023; 14(10): 1573-1584
URL: https://www.wjgnet.com/1948-9358/full/v14/i10/1573.htm
DOI: https://dx.doi.org/10.4239/wjd.v14.i10.1573

Lin C, Li ZL, Cai XL, Hu SY, Lv F, Yang WJ, Ji LN. Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis. World J Diabetes 2023; 14(10): 1573-1584 [PMID: 37970134 DOI: 10.4239/wjd.v14.i10.1573]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.